RARE Ultragenyx Pharmaceutical Inc.

NASDAQ
$17.73

Ultragenyx Pharmaceutical Inc. (RARE) Earnings News

Earnings press releases, previews and reviews for Ultragenyx Pharmaceutical Inc. (RARE), newest first. Our most recent is review: Ultragenyx Misses on Revenue, but Gene Therapy Approvals, $350 Million in Voucher Proceeds and Deep Cuts Push It Toward Profitability.